OncoCyte Corporation (OCX) financial statements (2021 and earlier)

Company profile

Business Address 15 CUSHING
IRVINE, CA 92618
State of Incorp. CA
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8111717222036
Cash and cash equivalents7101717221936
Short-term investments1000001
Receivables0000   
Prepaid expense0111000
Other current assets0000000
Other undisclosed current assets10000 0
Total current assets:9121818232037
Noncurrent Assets
Finance lease, right-of-use asset0      
Property, plant and equipment4444410
Long-term investments and receivables131414111111 
Long-term investments131414111111 
Intangible assets, net (including goodwill)24242424   
Goodwill9999   
Intangible assets, net (excluding goodwill)15151515   
Prepaid expense00000  
Other noncurrent assets00000  
Other undisclosed noncurrent assets4422200
Total noncurrent assets:4646454117121
TOTAL ASSETS:55586360403338
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4533212
Accounts payable0112001
Employee-related liabilities4421111
Debt3222111
Due to related parties    0 0
Other undisclosed current liabilities2223112
Total current liabilities:9977434
Noncurrent Liabilities
Long-term debt and lease obligation26652 0
Long-term debt, excluding current maturities22322  
Finance lease, liability00000 0
Operating lease, liability 433   
Liabilities, other than long-term debt781111   
Deferred income tax liabilities 000   
Business combination, contingent consideration, liability781111   
Other undisclosed noncurrent liabilities4   30 
Total noncurrent liabilities:13141716500
Total liabilities:22232423934
Stockholders' equity
Stockholders' equity attributable to parent33354037312934
Common stock157152150138125115114
Accumulated deficit(124)(117)(111)(101)(94)(86)(81)
Total stockholders' equity:33354037312934
TOTAL LIABILITIES AND EQUITY:55586360403338

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues1100   
Cost of revenue(1)(1)(0)(0)   
Gross profit:(0)(0)(0)(0)   
Operating expenses(9)(7)(9)(8)(8)(5)(5)
Other undisclosed operating income3100   
Operating loss:(6)(6)(9)(8)(8)(5)(5)
Nonoperating income (expense)(0)(1)(0)(0)(0)00
Interest and debt expense(0)  (0)(0)  
Loss from continuing operations before equity method investments, income taxes:(6)(7)(9)(9)(8)(5)(5)
Other undisclosed income from continuing operations before income taxes0  0   
Loss from continuing operations before income taxes:(6)(7)(9)(9)(8)(5)(5)
Income tax expense (benefit)0  (1)   
Net loss:(6)(7)(9)(10)(8)(5)(5)
Other undisclosed net income attributable to parent   20  
Net loss available to common stockholders, diluted:(6)(7)(9)(8)(8)(5)(5)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(6)(7)(9)(10)(8)(5)(5)
Comprehensive loss:(6)(7)(9)(10)(8)(5)(5)
Other undisclosed comprehensive income, net of tax, attributable to parent   20  
Comprehensive loss, net of tax, attributable to parent:(6)(7)(9)(8)(8)(5)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: